1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
B.T. Li(Memorial Sloan Kettering Cancer Center), David Planchard(Institut Gustave Roussy), Kōichi Goto(National Cancer Center Hospital East), Egbert F. Smit(Leiden University Medical Center), J. De Langen(The Netherlands Cancer Institute), Yasushi Goto(National Cancer Center Hospital East), Kiichiro Ninomiya(Okayama University Hospital), Toshio Kubo(Okayama University Hospital), M. Pérol(Centre de Recherche en Cancérologie de Lyon), Enriqueta Felip(Vall d'Hebron Hospital Universitari), H. Hayashi(Kindai University Hospital), Kazuhiko Nakagawa(Kindai University Hospital), Junichi Shimizu(Aichi Cancer Center), Misako Nagasaka(University of California, Irvine), Kaline Pereira(Daiichi Sankyo (United States)), Ayumi Taguchi(Daiichi-Sankyo (Japan)), Ahmed Ali(Daiichi Sankyo (Germany)), Maha Karnoub(Daiichi Sankyo (United States)), Rie Yonemochi(Daiichi Sankyo (United States)), Pasi A. Jänne(Dana-Farber Cancer Institute)
Cited by 34Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis